Evidence map›Paper›PMID 24470729›Full record

ReviewHippokratia2013

X-linked, COL4A5 hypomorphic Alport mutations such as G624D and P628L may only exhibit thin basement membrane nephropathy with microhematuria and late onset kidney failure.

A Pierides, K Voskarides, M Kkolou, M Hadjigavriel, C Deltas

Open access · greenAbstract readReview
In one paragraph

Review in Hippokratia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Kidney international reports · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Guidelines for Genetic Testing and Management of Alport Syndrome.Clinical journal of the American Society of Nephrology : CJASN · 2022
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. The Hypomorphic Variant p.(Gly624Asp) inFrontiers in pediatrics · 2019
    Article
  16. Article
  17. Identification of a NovelFrontiers in genetics · 2018
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

A PieridesDepartment of Nephrology, Hippocrateon Hospital, Nicosia, Cyprus ; Department of Biological Sciences and Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus.
K VoskaridesDepartment of Biological Sciences and Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus.
M KkolouDepartment of Nephrology, Larnaca General Hospital, Larnaca, Cyprus.
M HadjigavrielDepartment of Nephrology, Larnaca General Hospital, Larnaca, Cyprus.
C DeltasDepartment of Biological Sciences and Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus.
Larnaca College · CYUniversity of Cyprus · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alport syndrome (ATS) results from X-linked, COL4A5 mutations (85%) or from autosomal recessive homozygous or compound heterozygous COL4A3/A4 mutations (15%), associated with alternate thinning and thickening as well as splitting and lamellation of the glomerular basement membranes. In contrast, familial microhematuria with thin basement membranes is thought to result from heterozygous COL4A3/A4 mutations. This absolute separation may not always be true. Renal biopsies and molecular genetics were used to study microhematuric families in the Hellenic population we serve. The COL4A5 gene was studied by PCR and direct re-sequencing for new mutations, while PCR-RFLP was used to identify more carriers of known COL4A5 and COL4A3/A4 mutations. Molecular genetics in two undiagnosed microhematuric Cypriot families, revealed COL4A5 mutation P628L indicating X-linked ATS. Of nine males, seven developed end stage kidney disease (ESKD) between 31 and 56, while two are well at 51 and 57, exhibiting microhematuria and thin basement membrane nephropathy (TBMN). COL4A5 mutation G624D was also identified in six Greek families. Seventy five members had DNA tests and 37 proved positive. Four positive males developed ESKD at 61, 51, 50 and 39 years, while the remaining and all females showed only microhematuria. A literature search revealed eight papers with six similar hypomorphic COL4A5 mutations presenting as phenocopies of TBMN. In conclusion, X-linked COL4A5 ATS mutations produce a phenotypic spectrum with a) classical ATS with early onset ESKD, neurosensory deafness and ocular defects b) males with only ESKD and late deafness and c) males due to missense mutations, such as G624D and P628L that may only exhibit microhematuria, TBMN, mild chronic renal failure (CRF) or late onset ESKD. Consequently when investigating "benign familial hematuria" these and other similar X-linked COL4A5 mutations should also be searched for.

Indexed as

Alport syndromebenign familial hematuriaCOL4A3/COLA4/COL4A5 mutationshypomorphic COL4A5 mutationsphenotypic heterogeneitythin basement membrane nephropathy

Identifiers

PMID24470729
PMCPMC3872455
OpenAlexW2147730695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.